- Home
- RVPH vs ANL Comparison
RVPH vs ANL Comparison
Compare RVPH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- ANL
- Stock Information
- Founded
- RVPH 2006
- ANL 2004
- Country
- RVPH United States
- ANL Cayman Islands
- Employees
- RVPH N/A
- ANL N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- RVPH Health Care
- ANL
- Exchange
- RVPH Nasdaq
- ANL Nasdaq
- Market Cap
- RVPH 88.0M
- ANL 81.9M
- IPO Year
- RVPH N/A
- ANL 2023
- Fundamental
- Price
- RVPH $1.39
- ANL $2.22
- Analyst Decision
- RVPH Strong Buy
- ANL Strong Buy
- Analyst Count
- RVPH 5
- ANL 2
- Target Price
- RVPH $11.40
- ANL $9.00
- AVG Volume (30 Days)
- RVPH 1.4M
- ANL 5.8K
- Earning Date
- RVPH 04-14-2025
- ANL 03-04-2025
- Dividend Yield
- RVPH N/A
- ANL N/A
- EPS Growth
- RVPH N/A
- ANL N/A
- EPS
- RVPH N/A
- ANL N/A
- Revenue
- RVPH N/A
- ANL $5,000,000.00
- Revenue This Year
- RVPH N/A
- ANL N/A
- Revenue Next Year
- RVPH N/A
- ANL N/A
- P/E Ratio
- RVPH N/A
- ANL N/A
- Revenue Growth
- RVPH N/A
- ANL N/A
- 52 Week Low
- RVPH $0.60
- ANL $1.85
- 52 Week High
- RVPH $4.33
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- RVPH 31.30
- ANL 53.18
- Support Level
- RVPH $1.36
- ANL $2.15
- Resistance Level
- RVPH $1.88
- ANL $2.75
- Average True Range (ATR)
- RVPH 0.15
- ANL 0.15
- MACD
- RVPH -0.06
- ANL 0.01
- Stochastic Oscillator
- RVPH 7.59
- ANL 26.67
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.